Autism spectrum disorders - An emerging area in psychopharmacology

Psychopharmacology

Volumn 231, Issue 6, 2014, Pages 977-978

  Steckler, Thomas ^a   Spooren, Will ^b   Murphy, Declan ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTISM; DRUG DEVELOPMENT; EDITORIAL; FRAGILE X SYNDROME; HUMAN; NONVERBAL COMMUNICATION; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SOCIAL INTERACTION; VERBAL COMMUNICATION;

CHILD DEVELOPMENT DISORDERS, PERVASIVE; DRUG DISCOVERY; HUMANS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 84896714544     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3460-2     Document Type: Editorial

References (22)

1. Aigner S, Heckel T, Zhang JD, Andreae LC, Jagasia R (2013) Human pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dish. Psychopharmacology. doi: 10.1007/s00213-013-3332-1
2. Brugha TS, McManus S, Bankart J, Scott F, Purdon S, Smith J, Bebbington P, Jenkins R, Meltzer H (2011) Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry 68:459-465
3. Cadman T, Eklund H, Howley D, Hayward H, Clarke H, Findon J, Xenitidis K, Murphy D, Asherson P, Glaser K (2012) Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. J Am Acad Child Adolesc Psychiatry 51:879-888
4. CDC (2012) Prevalence of autism spectrum disorders - autism and developmental disabilitiesmonitoring network, 14 sites, United States, 2008. MMWR 61:1-19
5. Cocks G, Curran S, Gami P, Uwanogho D, Jeffries AR, Kathuria A, Lucchesi W, Wood V, Dixon R, Ogilvie C, Steckler T, Price J (2013) The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders. Psychopharmacology. doi: 10.1007/s00213-013-3196-4
6. Dage JL, Colvin EM, Fouillet A, Langron E, Roell WC, Li J, Mathur SX, Mogg AJ, Schmitt MG, Felder CC, Merchant KM, Isaac J, Broad LM, Sher E, Ursu D (2014) Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons. Psychopharmacology. doi: 10.1007/s00213-013-3384-2
7. Devine DP (2013) Self-injurious behaviour in autistic children: a neurodevelopmental theory of social and environmental isolation. Psychopharmacology. doi: 10.1007/s00213-013-3279-2
8. European Medicines Agency (2013) Concept paper on the development of medicinal products for the treatment of Autism Spectrum Disorder. EMA/CHMP/40896/2013
9. Hsia Y, Wong AYS, Murphy DGM, Simonoff E, Buitelaar JK, Wong ICK (2013) Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology. doi: 10.1007/s00213-013-3263-x
10. Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B (2013) The challenges of clinical trials in fragile X syndrome. Psychopharmacology. doi: 10.1007/s00213-013-3289-0
11. Kas MJ, Glennon JC, Buitelaar J, Ey E, Biemans B, Crawley J, Ring RH, Lajonchere C, Esclassan F, Talpos J, Noldus LPJJ, Burbach JPH, Steckler T (2013) Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology. doi: 10.1007/s00213-013-3268-5
12. Kas MJ, Modi ME, Saxe MD, Smith DG (2014) New technologies reveal the brain circuits of social behavior in rodents and advance the discovery of medications for autism spectrum disorder. Psychopharmacology. doi: 10.1007/s00213-014-3464-y
13. Khatri N, Simpson KL, Lin RCS, Paul IA (2013) Lasting neurobehavioral abnormalities in rats after neonatal activation of serotonin 1A and 1B receptors: possible mechanisms for serotonin dysfunction in autistic spectrum disorders. Psychopharmacology. doi: 10.1007/s00213-013-3242-2
14. Kleijer KTE, Schmeisser MJ, Krueger DD, Boeckers TM, Scheiffele P, Bourgeron T, Brose N, Burbach JPH (2014) Neurobiology of autism gene products: towards pathogenesis and drug targets. Psychopharmacology. doi: 10.1007/s00213-013-3403-3
15. Murphy D, Spooren W (2012) EU-AIMS: a boost to autism research. Nat Rev Drug Discov 11:815-816
16. Murray ML, Hsia Y, Glaser K, Simonoff E, Murphy DGM, Asherson PJ, Eklund H, Wong ICK (2013) Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology. doi: 10.1007/s00213-013-3140-7
17. Petrinovic MM, Künnecke B (2013) Neuroimaging endophenotypes in animal models of autism spectrum disorders: lost or found in translation? Psychopharmacology. doi: 10.1007/s00213-013-3200-z
18. Politte LC, McDougle CJ (2013) Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology. doi: 10.1007/s00213-013-3068-y
19. Pop AS, Levenga J, de Esch CEF, Buijsen RAM, Nieuwenhuizen IM, Li T, Isaacs A, Gasparini F, Oostra BA, Willemsen R (2012) Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology. doi: 10.1007/s00213-012-2947-y
20. Pop AS, Gomez-Mancilla B, Neri G, Willemsen R, Gasparini F (2013) Fragile X syndrome: a preclinical review onmetabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology. doi: 10.1007/s00213-013- 3330-3
21. Ruggeri B, Sarkans U, Schumann G, Persico AM (2013) Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology. doi: 10.1007/s00213-013-3290-7
22. Vorstman JAS, Spooren W, Persico AM, Collier DA, Aigner S, Jagasia R, Glennon JC, Buitelaar JK (2013) Using genetic findings in autism for the development of new pharmaceutical compounds. Psychopharmacology. doi: 10.1007/s00213-013-3334-z